Evidence map›Paper›PMID 36894196›Full record

ReviewRMD open2023

IgG4-related disease administered dupilumab: case series and review of the literature.

Masatoshi Kanda, Ryuta Kamekura, Masanari Sugawara, Ken Nagahata, Chisako Suzuki, Kenichi Takano, Hiroki Takahashi

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in RMD open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
9.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Management of IgG4-Related Disease.Current rheumatology reports · 2026
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Omics in IgG4-related disease.Chinese medical journal · 2025
    Review
  15. Are there atypical sites of IgG4 related disease in head and neck region? Personal experience and literature review.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025
    Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Masatoshi KandaDepartment of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan mkanda@sapmed.ac.jp.ORCID 0000-0003-3468-3586
Ryuta KamekuraDepartment of Otolaryngology-Head and Neck Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan.
Masanari SugawaraDepartment of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Ken NagahataDepartment of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Chisako SuzukiDepartment of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Kenichi TakanoDepartment of Otolaryngology-Head and Neck Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan.
Hiroki TakahashiDepartment of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Sapporo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dupilumab (DUP) is a monoclonal antibody that acts on the interleukin (IL)-4 receptor alpha, which inhibits IL-4 and IL-13 signalling and is approved for type 2 inflammatory diseases such as asthma, chronic rhinosinusitis with nasal polyposis and atopic dermatitis; however, the efficacy of DUP to IgG4-related disease (IgG4-RD) is under discussion due to the controversial outcomes based on the several case reports. Here, we reviewed the efficacy of DUP in four consecutive patients with IgG4-RD in our institute and the previous literature.All patients administered DUP fulfilled the 2019 ACR/EULAR classification criteria for IgG4-RD complicated with severe asthma and chronic rhinosinusitis with nasal polyposis. Two cases were administered DUP without systemic glucocorticoids (GCs), and in 6 months, the volume of swollen submandibular glands (SMGs) was reduced by approximately 70%. Two cases receiving GCs successfully reduced their daily dose of GCs (10 and 50% reduction, respectively) with dupilumab in 6 months. In all four cases, serum IgG4 concentration and IgG4-RD responder index decreased in 6 months.DUP reduced the volume of the swollen SMGs, serum IgG4 levels, responder index and the daily dose of GCs in patients with IgG4-RD with severe asthma or eosinophilic rhinosinusitis in 6 months.The efficacy of DUP to IgG4-RD is under discussion due to the limited case reports with controversial outcomes. Here, we demonstrated that two patients with IgG4-RD treated by DUP without systemic GCs, showed volume reduction of swollen SMGs and two cases showed GC-sparing effects by DUP. DUP can ameliorate the disease activity and be a steroid-sparing agent in patients with IgG4-RD.

Indexed as

AsthmaImmunoglobulin G4-Related DiseaseAntibodies, Monoclonal, HumanizedGlucocorticoidsHumansImmunoglobulin GAntibodies, Monoclonal, HumanizeddupilumabGlucocorticoidsImmunoglobulin Gbiological therapycytokinesglucocorticoidsimmune system diseasestherapeutics

Identifiers

PMID36894196
PMCPMC10008221
OpenAlexW4323669888

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.